A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

A Trial Investigating Semaglutide and SNAC Concentrations in Breastmilk Following Administration of Multiple Doses of Oral Semaglutide in Healthy, Lactating Females

Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg semaglutide.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2
• Intervention / Treatment: Drug: Oral semaglutide

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • San Antonio, Texas, United States, 78209
      • ICON Early Phase Services, LLC
  • Utah
    • Millcreek, Utah, United States, 84124
      • ICON-Salt Lake City

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy, female subjects who have given birth at least 3 months prior to screening and who breastfeed (breastfeeding is defined by feeding the baby milk produced by the mother. Using a breast pump to collect milk and subsequently feeding it to the baby by bottle, is also defined as breastfeeding ) their infant to an extent, where the majority of the infant's total energy intake is from breastfeeding and sufficient milk is produced to fulfil the trial requirements, as judged by the investigator.
• Agree to abstain from breastfeeding their infant from first dose of oral semaglutide to the "End of trial" visit (total of 47 days) to avoid potentially exposing their child to semaglutide and SNAC.
• The breastfed infant is able to feed from a bottle (expenses related to alternative infant nutrition during trial participation will be covered by Novo Nordisk) prior to screening.
• Age above or equal to 18 years at the time of agreement to take part.
• Body mass index (BMI) between 20.0 and 32.4 kg/m^2 (both inclusive).

Exclusion Criteria:

• Female who is pregnant or intends to become pregnant or is of child-bearing potential and not using an effective contraceptive method.
• Glycated haemoglobin (HbA1c) greater than or equal to 6.5 % (48 mmol/mol) at screening.
• Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
• History (as declared by the subject or reported in the medical records) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
• Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by the subject or reported in the medical records).
• Presence or history (as declared by the subject or reported in the medical records) of malignant neoplasm within 5 years prior to the day of screening (basal or squamous cell skin cancer, or any carcinoma in-situ is allowed).
• Presence or history (as declared by the subject or reported in the medical records) of pancreatitis (acute or chronic).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Oral semaglutide; All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.	Drug: Oral semaglutide; Oral semaglutide once daily for a total of 10 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk)	nmol*h/L	From 0 to 24 hours after the 10th dosing (day 10)
Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average semaglutide milk concentration during a dosing interval after the 10th dosing (Cavg,sema,D10,milk)	nmol/L	From 0 to 24 hours after the 10th dosing (day 10)
Maximum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,milk)	nmol/L	From 0 to 24 hours after the 10th dosing (day 10)
Minimum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmin,sema,D10,milk)	nmol/L	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum semaglutide milk concentration during a dosing interval after the 10th dosing (tmax,sema,D10,milk)	Hours	From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant semaglutide dose	mg/kg/day	From 0 to 24 hours after the 10th dosing (day 10)
Relative daily infant semaglutide dose		From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC milk concentration during a dosing interval after the 10th dosing (Cavg,SNAC,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC milk concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC milk concentration during a dosing interval after the 10th dosing (Cmin,SNAC,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC milk concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,milk)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC dose	ng/kg/day	From 0 to 24 hours after the 10th dosing (day 10)
Relative daily infant SNAC dose		From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E494 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,milk)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cavg,E494,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmin,E494,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E494 milk concentration after the 10th dosing (tmax,E494,D10,milk)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E494 dose	ng/kg/day	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E506 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,milk)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cavg,E506,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmin,E506,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E506 milk concentration after the 10th dosing (tmax,E506,D10,milk)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E506 dose	ng/kg/day	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1245 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,milk)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cavg,E1245,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmin,E1245,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1245 milk concentration after the 10th dosing (tmax,E1245,D10,milk)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E1245 dose	ng/kg/day	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1246 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,milk)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cavg,E1246,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmin,E1246,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1246 milk concentration in milk after the 10th dosing (tmax,E1246,D10,milk)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E1246 dose	ng/kg/day	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1247 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,milk)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cavg,E1247,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmin,E1247,D10,milk)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1247 milk concentration after the 10th dosing (tmax,E1247,D10,milk)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E1247 dose	ng/kg/day	From 0 to 24 hours after the 10th dosing (day 10)
Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,plasma)	nmol*h/L	From 0 to 24 hours after the 10th dosing (day 10)
Maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,plasma)	nmol/L	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (tmax,sema,D10,plasma)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,plasma)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC plasma concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,plasma)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC plasma concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,plasma)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E494 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,plasma)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,plasma)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (tmax,E494,D10,plasma)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E506 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,plasma)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,plasma)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (tmax,E506,D10,plasma)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1245 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,plasma)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,plasma)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (tmax,E1245,D10,plasma)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1246 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,plasma)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,plasma)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (tmax,E1246,D10,plasma)	hours	From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1247 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,plasma)	ng*h/mL	From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,plasma)	ng/mL	From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)	hours	From 0 to 24 hours after the 10th dosing (day 10)

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S
• Investigators: Study Director: Clinical Transparency (dept. 1452), Novo Nordisk A/S

Study record dates

Study Major Dates

• Study Start (Actual): September 10, 2021
• Primary Completion (Actual): May 26, 2023
• Study Completion (Actual): July 3, 2023

Study Registration Dates

• First Submitted: March 23, 2021
• First Submitted That Met QC Criteria: March 23, 2021
• First Posted (Actual): March 26, 2021

Study Record Updates

• Last Update Posted (Actual): February 22, 2024
• Last Update Submitted That Met QC Criteria: February 21, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: NN9924-4669; U1111-1253-4467 (Other Identifier: World Health Organization (WHO))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No